PROCLAIM_2B | R Documentation |
Kaplan-Meier digitized data from PROCLAIM, figure 2B (PMID 26811519). A reported sample size of 598 for a primary endpoint of OS in lung cancer.
PROCLAIM_2B
A data frame of 598 observations and 3 variables:
time | event time (in months) | |
event | PFS event indicator (0 : no event, 1 : event) |
|
arm | treatment arms (eto_cis, pem_cis) | |
Senan S, Brade A, Wang L-H, et al. PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non-Small-Cell Lung Cancer. J Clin Oncol 2016; 34: 953–62.
summary(PROCLAIM_2B)
kmplot(PROCLAIM_2B)
Add the following code to your website.
For more information on customizing the embed code, read Embedding Snippets.